# Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

> **NCT03074318** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Leiomyosarcoma
- Metastatic Liposarcoma
- Unresectable Leiomyosarcoma
- Unresectable Liposarcoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT03074318
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-28
- **Primary completion:** 2020-11-15
- **Final completion:** 2020-11-15
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Terminated due to PI leaving institution
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074318, "Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03074318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*